Alternatively, individuals can access the call by dialing the Toll-Free Dial-In Number: (866) 211-4597, or the International Dial-In Number: (647) 689-6853 outside North America, both with passcode 2245817. Over the last four years, GRAILs talented team has made exceptional progress in developing the technology and clinical data required to launch the GalleriTMmulti-cancer screening test. Multi-cancer early detection is better for patients, their physicians, and payors. }.q4default .prngen14{ The base stock consideration was subject to a collar, where the number of shares issued at closing varied in the event the 20-trading-day volume weighted average price of Illumina stock as of 10 trading days prior to closing is between $295 and $399 but was fixed at 11.3 million shares if such volume weighted average share price is above $399, which is where the stock has traded over the last couple months. After submitting your request, you will receive an activation email to the requested email address. So Illumina are pushing forward with their GRAIL acquisition. GRAIL stockholders, including Illumina, are entitled to cash consideration of approximately $3.5 billion or, excluding Illumina, approximately $3.1 billion. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Grail's focus on liquid biopsy gives Illumina a significant new growth market. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the unsubscribe section below. The alternative additional stock consideration (that GRAIL stockholders could elect to receive in lieu of CVRs) consisted of up to $850 million of shares of Illumina common stock, with the number of shares issued capped at a specified amount if the 20-trading-day volume weighted average price of Illumina stock as of 10 trading days prior to closing is less than $280, which did not occur. About a month ago, Grail launched Galleri its long-awaited early cancer detection test through the Clinical Laboratory Improvement Amendments of 1988 (CLIA). }.q4default .prngen8{ This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Courtesy of Grail Listen to the article 2 min Illumina is continuing to evaluate "strategic options" for Grail as it faces antitrust pushback for its $7.1 billion acquisition of the maker of blood tests used to detect cancer, according to analysts at J.P. Morgan. Illumina will host a conference call to discuss the transaction today, September 21, 2020 at 8:00 a.m. EDT. jcraighead@grailbio.com. To do otherwise, Illumina said, is to treat Illumina and GRAIL as guinea pigs without even letting them know, depriving them of any advance warning of the Commission's paradigm shift in the review of mergers in the EU. In connection with the proposed transaction, Illumina intends to file with the SEC a registration statement on Form S-4 that will include a preliminary prospectus with respect to Illuminas common stock and contingent value rights to be issued in the proposed transaction and a consent solicitation statement of GRAIL in connection with the proposed transaction. Galleri is among the most promising new tools in the fight against cancer, and we are thrilled to welcome GRAIL back to Illumina to help transform cancer care using genomics and our NGS platform, said Francis deSouza, Illuminas President and Chief Executive Officer. BORDER-COLLAPSE: COLLAPSE Illumina will pay $8B to acquire Grail, the Bill Gates and Jeff Bezos-backed cancer detection company. The FTC's March 2021 complaint alleged that Illumina's $7.1 billion proposed acquisition of Grail would diminish innovation in the U.S. market for MCED tests. (c) During the third quarter of 2022, the company recognized $3.91 billion in goodwill impairment related to . Karen Birmingham, PhD Unlistedfactors may present significant additional obstacles to the realization of forward-looking statements. September 21, 2020. ", "The merger with Illumina will get the Galleri test to people far faster. 650-484-0690 By holding GRAIL separate while proceedings are ongoing, Illumina is positioned to abide by whatever final decision is reached in these legal processes. BORDER-RIGHT:1pt Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Grail plans to launch its test for early detection of cancers, Galleri, next year. For Research Use Only. In advance of this anticipated issuance, Illumina has obtained financing commitments for a $1.0 billion bridge facility with Goldman Sachs Bank USA. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Some small fraction of these fragments w In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "may," "target," similar expressions and variations or negatives of these words. We expect the transaction will be accretive to Illumina revenue starting in 2021, and to meaningfully accelerate revenue growth over time. You can sign up for additional alert options at any time. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. As we accelerate our path to clinical leadership and the path to multi-cancer early detection, we will continue to drive significant value creation for our stockholders., Cancer is one of societys most significant challenges, with most cancer being detected too late, said Hans Bishop, Chief Executive Officer of GRAIL. The reasons to reunite the two companies are compelling: "Just as we are now able to screen for early-stage diabetes and high cholesterol, we will soon be able to conduct multi-cancer early detection with a simple blood test in your doctor's office," said Francis deSouza, Chief Executive Officer of Illumina. BORDER-LEFT:0pt Bio-IT Platform, TruSight In September 2020, Illumina acquired GRAIL for $8 billion. Illumina closed the acquisition of Grail on Aug. 18, 2021. Right now, the Galleri test is available but costs $950 because . BORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 1pt solid; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em jcraighead@grailbio.com. Upon closing of the transaction, current Illumina stockholders are expected to own approximately 93% of the combined company, while GRAIL stockholders are expected to own approximately 7% based on the mid-point of the collar. The acquisition will enable GRAIL to leverage Illumina's as global commercial, clinical and operations capabilities, accelerating their mission and allowing us to impact more people faster. GRAIL raised approximately $2 billion to support its innovative technology platform and develop Galleri. This document is not a substitute for consent solicitation statement/prospectus or registration statement or any other document which Illumina may file with the SEC. BORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 2pt double; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.67em These risks, as well as other risks associated with the transaction, are more fully discussed in the Consent Solicitation Statement/Prospectus that is included in the Registration Statement. }. The collar on the stock consideration will ensure that GRAIL stockholders excluding Illumina receive a number of Illumina shares equal to approximately $4 billion in value if the 20-trading-day volume weighted average price of Illumina stock as of 10 trading days prior to closing is between $295 and $399. The transaction is subject to customary closing conditions, including applicable regulatory approvals. Alternatively, individuals can access the call by dialing the Toll-Free Dial-In Number: (866) 211-4597, or the International Dial-In Number: (647) 689-6853 outside North America, both with passcode 2245817. Retailer Reg: 2019--2018 | GRAIL and Illumina have a long history. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)-- Cautionary Notes on Forward-Looking Statements. Sequence Hub, BaseSpace The Federal Trade Commission filed an administrative complaint and authorized a federal court lawsuit to block Illumina's $7.1 billion proposed acquisition of Graila maker of a non-invasive, early detection liquid biopsy test that can screen for multiple types of cancer in asymptomatic patients at very early stages using DNA sequencing. Illumina's acquisition of GRAIL will accelerate access and adoption of this life-saving test worldwide. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. }.q4default .prnsbr0{ All trademarks are the property of Illumina, Inc. or their respective owners.For specific trademark information, see www.illumina.com/company/legal.html. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. As a result, the total number of shares issued was reduced by a number of shares with a value equal to such withholding obligation, and an equivalent cash amount was paid by Illumina in respect of such withholding obligations. This communication contains forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em 518-423-5907 Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Revenue above $1 billion each year would be subject to a 9% contingent payment right during this same period. https://www.businesswire.com/news/home/20200921005256/en/, Media: The European Commission this month vetoed a deal in which the leading DNA sequencing company Illumina acquired DNA-based cancer diagnostics specialist Grail, saying the ban is needed to leave the market open for competitor products that are in development. Following the call, a replay will be posted on Illumina website and will be available for at least 30 days following posting. Illumina owned 12.0% of the outstanding equity interests in GRAIL on a fully diluted basis. We are excited about this next step in our journey to transform cancer detection and outcomes and create value for patients and their families and communities, health care providers and payors, employers, and stockholders.. After submitting your request, you will receive an activation email to the requested email address. Grail stockholders excluding . This will reflect a 2.5% payment right to the first $1 billion of revenue each year for 12 years. GRAIL raised approximately $2 billion to support its innovative technology platform and develop Galleri. Combining forces with Illumina enables broader and faster adoption of GRAILs innovative, multi-cancer early detection blood test, enhancing patient access and expanding global reach. Products, DRAGEN v4.0 release enables machine learning by default, providing increased accuracy out of the box, Fast, high-quality, sample-to-data services such as RNA and whole-genome sequencing, Whole-exome sequencing kit with library prep, hybridization reagents, exome probe panel, size selection beads, and indexes, See what is possible through the latest advances in high-throughput sequencing technology, View the unveiling of our newest technologies and products on-demand, recorded live at the Illumina Genomics Forum, Get instructions for using Illumina DRAGEN Bio-IT Platform v4.0, A campus lab sequences dust from vacuum bags to understand the variants and viral load of SARS-CoV-2 and other viruses, Mapping genetic diversity to identify where confiscated gorillas come from and boost survival rates, Explore the advantages of NGS for analysis of gene expression, gene regulation, and methylation, The NovaSeq 6000Dx is our first IVD-compliant high-throughput sequencing instrument for the clinical lab, .q4default .prngen6{ Illumina, the global leader in DNA sequencing, first announced its intention to acquire GRAIL nearly a year ago, reuniting Illumina with GRAIL four years after it was spun off. The transaction is subject to customary closing conditions, including applicable regulatory approvals. But GRAIL currently faces a number of hurdles to widespread distribution and adoption. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Following the call, a replay will be posted on Illumina website and will be available for at least 30 days following posting. In connection with the transaction, GRAIL stockholders will also receive contingent value rights, which will entitle holders to receive future payments representing a pro rata portion of certain GRAIL-related revenues each year for a 12-year period. We believe multi-cancer early detection technology could address a tremendous unmet need and reduce the cancer burden worldwide. Current Price $200.87 The chances are certainly higher now that the deal won't happen. }.q4default .prntal{ }.q4default .prnvab{ The cash consideration to GRAIL stockholders excluding Illumina of approximately $3.1 billion is expected to be funded using balance sheet cash of both Illumina and GRAIL plus up to $1 billion in capital raised through either a debt or equity issuance. Illumina currently holds 14.5% of GRAILs shares outstanding, and approximately 12% on a fully diluted basis. Not for import or sale to the Australian general public. Accelerates Commercialization and Adoption of Transformative Multi-Cancer Screening Test with Potential to Detect More Cancers Earlier and Enable Better Outcomes, Adds Multi-Disciplinary Team and Capabilities Harnessing the Power of Next-Generation Sequencing (NGS), Population Scale Clinical Studies, and Machine Learning to Address One of Medicines Greatest Challenges, Brings Significant New Growth Opportunities in the Clinical Setting, NGS Oncology Testing Total Addressable Market Anticipated to Grow to $75 Billion by 2035. 858-882-2172 General Inquiries. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to make any filing or take other action required to consummate such transaction in a timely matter or at all. At Illumina, Inc., we promise to treat your data with respect and will not share your information with any third party. NEW YORK - Illumina and Grail said on Monday morning that they have entered into a definitive acquisition agreement under which Illumina will purchase Grail for $8 billion in cash and stock. Salli Schwartz, Vice President lllumina Investor Relations5200 Illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021. This document is not a substitute for consent solicitation statement/prospectus or registration statement or any other document which Illumina may file with the SEC. In connection with the transaction, GRAIL stockholders will also receive contingent value rights, which will entitle holders to receive future payments representing a pro rata portion of certain GRAIL-related revenues each year for a 12-year period. Salli Schwartz, Vice President lllumina Investor Relations5200 Illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. This includes $3.5 billion. Illumina expects to close the transaction in the second half of 2021. GRAIL was founded by Illumina in 2016 and was spun out as a standalone company, powered by Illuminas NGS technology, to develop state-of-the-art data science and machine learning and create the atlas of cancer signals in the blood, enabling multi-cancer early detection tests. A federal judge recently dismissed the Federal Trade Commission's challenge of Illumina Inc.'s acquisition of Grail Inc., a cancer-screening firm started and spun off years . In addition, GRAIL stockholders will receive future payments representing a tiered single digit percentage of certain GRAIL-related revenues. & Pipeline Setup, Sequencing Data Illumina, San Diego's largest biotech company and a sequencing giant, thinks the answer is to let it acquire Grail. 2022 Illumina, Inc. All rights reserved. GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL has no business in the EU, and the company believes that the European Commission does not have jurisdiction to review the merger as the EU merger thresholds are not met, nor are they met in any EU member state. Illumina to Acquire GRAIL Launching a New Era in Cancer Detection September 21, 2020. Illumina currently holds 14.5% of GRAILs shares outstanding, and approximately 12% on a fully diluted basis. Illumina is committed to working through the ongoing FTC administrative process, and as always, will abide by whatever outcome is ultimately reached in the US courts. https://www.businesswire.com/news/home/20200921005256/en/, Media: Morgan Stanley & Co. LLC is serving as exclusive financial advisor and Latham & Watkins LLP is serving as legal advisor to GRAIL. Not for use in diagnostic procedures (except as specifically noted). "A one-year acceleration of access to the Galleri test for the US population has the potential to save 10,000 lives over a 9-year period.". Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Illuminas financial condition, results of operations, credit rating or liquidity. BORDER-BOTTOM:0pt If the transaction is nullified, then Illumina receives their cash and shares back. }.q4default .prnsbb0{ Together, we have an important opportunity to introduce routine and broadly available blood-based screening that enables early cancer detection when treatment can be more effective and less costly. Following the completion of the transaction, GRAIL will operate as a standalone division within Illumina with a dedicated leadership team to ensure continuation of GRAILs success. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicines greatest challenges. Grail was originally formed in 2015 as a subsidiary of Illumina, but Illumina spun it off in 2017 so that . }.q4default .prntar{ You must click the activation link in order to complete your subscription. Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. Morgan Stanley & Co. LLC is serving as exclusive financial advisor and Latham & Watkins LLP is serving as legal advisor to GRAIL. Illumina is improving human health by unlocking the power of the genome. From fighting the COVID-19 pandemic to matching cancer patients to therapies, Illumina's mandate is to save lives and transform healthcare. Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of Illuminas business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of Illuminas common stock and on Illuminas operating results (vi) the risks and costs associated with the integration of, and the ability of Illumina to integrate, GRAILs business successfully and to achieve anticipated synergies, (vii) risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (viii) the risks and costs associated with the development and commercialization of, and Illuminas ability to develop and commercialize, GRAILs products; (ix) the risk that disruptions from the proposed transaction will harm Illuminas business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in Illuminas most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) managements response to any of the aforementioned factors. }.q4default .prnsbt0{ Salli Schwartz, Vice President lllumina Investor Relations 5200 Illumina Way San Diego, CA 92122. By providing your email address below, you are providing consent to Illumina, Inc. to send you the requested Investor Email Alert updates. }.q4default .prngen9{ Salli Schwartz, Vice President lllumina Investor Relations5200 Illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the unsubscribe section below. ir@illumina.com, For GRAIL Stockholders: To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Illumina does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. 2 Additional Information and Where to Find It. }.q4default .prnbcc{ (a) See the tables included in "Results of Operations - Non-GAAP" section below for reconciliations of these GAAP and non-GAAP financial measures. Illumina strongly believes that acquiring GRAIL is in the best interest of patients, is procompetitive, and benefits the multi-cancer early detection field as a whole. }.q4default .prnsbl0{ }.q4default .prnpr6{ Morgan Stanley & Co. LLC is serving as exclusive financial advisor and Latham & Watkins LLP is serving as legal advisor to GRAIL. GRAIL's first employees were part of Illumina, which still owns 12 percent of the company. Illumina currently holds 14.5% of GRAILs shares outstanding, and approximately 12% on a fully diluted basis. The General Court of the European Union will hear Illumina's jurisdictional challenge later this year. The rumors are indeed true - Illumina is attempting to acquire early cancer detection specialist Grail for about $8 billion. 858-882-2172 Illumina is improving human health by unlocking the power of the genome. GRAIL GRAILs initial thesis was that they'd sequence cfDNA (cell free DNA, shed from cells in blood) at very high depth. Jacquie Ross, CFA TEXT-ALIGN: RIGHT Illumina, Inc. ILMN recently announced the completion of its long-standing and highly-disputed acquisition of GRAIL -- a healthcare company focused on life-saving early detection of multiple . Interpretation, Certificates (CofC, CofA) and Master Lot Sheets, AmpliSeq for Illumina Cancer Hotspot Panel v2, AmpliSeq for Illumina Comprehensive Cancer Panel, Breast Cancer Target Identification with High-Throughput NGS, The Complex World of Pan-Cancer Biomarkers, Microbiome Studies Help Refine Drug Discovery, Identifying Multidrug-Resistant Tuberculosis Strains, Investigating the Mysterious World of Microbes, IDbyDNA Partnership on NGS Infectious Disease Solutions, Infinium iSelect Custom Genotyping BeadChips, 2020 Agricultural Greater Good Grant Winner, 2019 Agricultural Greater Good Grant Winner, Gene Target Identification & Pathway Analysis, TruSeq Methyl Capture EPIC Library Prep Kit, Genetic Contributions of Cognitive Control, Challenges and Potential of NGS in Oncology Testing, Partnerships Catalyze Patient Access to Genomic Testing, Patients with Challenging Cancers to Benefit from Sequencing, NIPT vs Traditional Aneuploidy Screening Methods, SNP Array Identifies Inherited Genetic Disorder Contributing to IVF Failures, NIPT Delivers Sigh of Relief to Expectant Mother, Education is Key to Noninvasive Prenatal Testing, Study Takes a Look at Fetal Chromosomal Abnormalities, Rare Disease Variants in Infants with Undiagnosed Disease, A Genetic Data Matchmaking Service for Researchers, Using NGS to Study Rare Undiagnosed Genetic Disease, Progress for Patients with Rare and Undiagnosed Genetic Diseases, https://www.prnewswire.com/news-releases/illumina-acquires-grail-to-accelerate-patient-access-to-life-saving-multi-cancer-early-detection-test-301358390.html, Illumina Reports Financial Results for Second Quarter of Fiscal Year 2021, Illumina To Webcast Upcoming Investor Conference. Under the terms of the agreement, at closing, GRAIL stockholders (including Illumina) will receive total consideration of $8 billion, consisting of $3.5 billion in cash and $4.5 billion in shares of Illumina common stock, subject to a collar. The deal will save lives. When Illumina entered the non-invasive prenatal testing space, prices dropped, reimbursement expanded, the number of providers increased, and more expectant parents had access to testing. Over the last four years, GRAILs talented team has made exceptional progress in developing the technology and clinical data required to launch the GalleriTM multi-cancer screening test. GRAIL financial results are reflected for the period after the acquisition. BORDER-TOP:black 0pt The final acquisition price was $8 billion. For Research Use Only. Illumina may also file other documents with the SEC regarding the proposed transaction. 650-484-0690 Under the terms of the agreement, at closing, GRAIL stockholders (including Illumina) will receive total consideration of $8 billion, consisting of $3.5 billion in cash and $4.5 billion in shares of Illumina common stock, subject to a collar. Illumina to Acquire GRAIL | New Era in Cancer Detection Expands Illumina's role beyond technology innovator and application enabler, to healthcare diagnostics and testing Enables Illumina to participate more fully in high value clinical market (revenue tied to clinical value, not sequencing output) Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. But the deal isn't final. These risks, as well as other risks associated with the proposed transaction, will be more fully discussed in the consent solicitation statement/prospectus that will be included in the registration statement on Form S-4 that will be filed with the SEC in connection with the proposed transaction. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. View source version on businesswire.com: This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. BORDER-TOP-COLOR:; VERTICAL-ALIGN: BOTTOM; BORDER-LEFT-COLOR:; BORDER-BOTTOM-COLOR:; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-RIGHT-COLOR:; PADDING-RIGHT:0.67em }.q4default .prnml40{ We are also spending approximately $0.4 billion in cash to cover the tax withholding requirements from net settling shares of Illumina common stock issuable to GRAIL employees. Illumina is a U.S. biotech company and a leader in next-generation sequencing systems (NGS). In September 2020, Illumina agreed to acquire Grail, a U.S.-based developer of blood tests for multiple early stage cancers, for US$7.1 billion. BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em Customer Dashboard, Infrastructure Revenue above $1 billion each year would be subject to a 9% contingent payment right during this same period. Illumina will offer GRAIL stockholders the option to receive additional cash and/or stock consideration, in an amount to be determined prior to closing, in lieu of the contingent value rights. With an eye on the virtually untapped market for early cancer detection, sequencing giant Illumina announced today that it will acquire the remaining portion of GRAIL that is does not already own in a cash and stock deal valued at approximately $8 billion. Host: https://www.illumina.com | Alternatively, individuals can access the call by dialing the Toll-Free Dial-In Number: (866) 211-4597, or the International Dial-In Number: (647) 689-6853 outside North America, both with Conference ID:9955888. Illumina Inc, a global leader in genomics, said on Monday that it would acquire Grail, a healthcare company whose mission is focused on early detection of multi-cancer, for cash and stock. GRAIL was founded by Illumina in 2016 and was spun out as a standalone company, powered by Illuminas NGS technology, to develop state-of-the-art data science and machine learning and create the atlas of cancer signals in the blood, enabling multi-cancer early detection tests. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law. Illumina does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. The acquisition of the Grail will expand Illumina's portfolio with the addition of cancer screening, diagnosis and cancer monitoring solutions. Cautionary Notes on Forward-Looking Statements. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to make any filing or take other action required to consummate such transaction in a timely matter or at all. Illumina, and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. Grail was originally formed in 2015 as a. The number of shares issued reflects approximately 11.3 million shares of base stock consideration and approximately 0.7 million shares of additional stock consideration (in lieu of CVRs), reduced by approximately 1.4 million shares to which Illumina is entitled in respect of its GRAIL stock and approximately 0.8 million shares in respect of GRAIL employee net share settlement. }.q4default .prnsbr1{ Investors and security holders may obtain free copies of the registration statement on Form S-4 (when available), which will include the consent solicitation statement/prospectus, and other documents filed with the SEC by Illumina through the website maintained by the SEC atwww.sec.gov, through Illuminas Investor Relations page (investor.Illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122. Illumina will host a conference call to discuss the transaction today, September 21, 2020 at 8:00 a.m. EDT. Together, we have an important opportunity to introduce routine and broadly available blood-based screening that enables early cancer detection when treatment can be more effective and less costly. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. TEXT-ALIGN: LEFT No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law. Illumina's (NASDAQ: ILMN) plans to reduce prices and allow competitors continued access to its technology had not yet convinced EU antitrust regulators reviewing the life sciences company's $7.1B. SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)-- MARGIN-LEFT:3.33em; MARGIN-TOP:0em; MARGIN-BOTTOM:0em We believe multi-cancer early detection technology could address a tremendous unmet need and reduce the cancer burden worldwide. }.q4default .prnpr8{ Illumina (ILMN) to acquire GRAIL (GRAL) for $8B - Slideshow Sep. 21, 2020 5:12 PM ET Illumina, Inc. (ILMN) 8 Comments SA Transcripts 131.54K Follower s The following slide deck was published by. Aug 24 (Reuters) - The U.S. Federal Trade Commission on Tuesday said it seeks to unwind life science company Illumina Inc's (ILMN.O) $7.1 billion acquisition of Grail Inc (GRAL.O), alleging. 646-355-2111 GRAIL'sGalleriblood test detects 50 different cancers before they are symptomatic. While the list of factors presented here is, and the list of factors to be presented in the registration statement on Form S-4 are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. In total, we will be issuing approximately 9.8 million shares of Illumina common stock as part of this acquisition. Holders of approximately 47% of GRAIL equity interests and/or awards (on a fully diluted basis), or 54% excluding Illumina, elected to receive the CVR consideration. GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. Apps, DRAGEN As previously disclosed, the merger consideration for Illumina's acquisition of GRAIL included cash and shares of Illumina common stock, as well as contingent value rights (CVRs) or additional shares of Illumina common stock. Galleri is expected to launch commercially in 2021 as a multi-cancer, laboratory developed test for early cancer detection from blood. As we accelerate our path to clinical leadership and the path to multi-cancer early detection, we will continue to drive significant value creation for our stockholders., Cancer is one of societys most significant challenges, with most cancer being detected too late, said Hans Bishop, Chief Executive Officer of GRAIL. BORDER-BOTTOM:black 1pt solid Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of Illuminas business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of Illuminas common stock and on Illuminas operating results (vi) the risks and costs associated with the integration of, and the ability of Illumina to integrate, GRAILs business successfully and to achieve anticipated synergies, (vii) risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (viii) the risks and costs associated with the development and commercialization of, and Illuminas ability to develop and commercialize, GRAILs products; (ix) the risk that disruptions from the proposed transaction will harm Illuminas business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in Illuminas most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) managements response to any of the aforementioned factors. The Commission opened an in-depth investigation into the proposed acquisition last July, citing concerns that Illumina could engage in vertical input foreclosure . You can sign up for additional alert options at any time. Illumina's acquisition of GRAIL will accelerate the global adoption of Galleri, the only blood test capable of detecting more than 50 different types of cancer with >99% specificity. This will reflect a 2.5% payment right to the first $1 billion of revenue each year for 12 years. BORDER-TOP:0pt 518-423-5907 858.291.6421 ir@illumina.com kbirmingham@illumina.com, Matt Burns Illumina does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Upon closing of the transaction, current Illumina stockholders are expected to own approximately 93% of the combined company, while GRAIL stockholders are expected to own approximately 7% based on the mid-point of the collar. The acquisition drew concerns in the U.S. and . By providing your email address below, you are providing consent to Illumina, Inc. to send you the requested Investor Email Alert updates. Save for later. The Transaction was not reportable at EU or Member State level. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Accelerates Commercialization and Adoption of Transformative Multi-Cancer Screening Test with Potential to Detect More Cancers Earlier and Enable Better Outcomes, Adds Multi-Disciplinary Team and Capabilities Harnessing the Power of Next-Generation Sequencing (NGS), Population Scale Clinical Studies, and Machine Learning to Address One of Medicines Greatest Challenges, Brings Significant New Growth Opportunities in the Clinical Setting, NGS Oncology Testing Total Addressable Market Anticipated to Grow to $75 Billion by 2035. SAN DIEGO & MENLO PARK, Calif.-(BUSINESS WIRE)- Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the . Last month, the European Commission (EC) announced that it had completed its review of the acquisition and found that Illumina's acquisition of GRAIL was "incompatible with the internal market in Europe because it results in a significant impediment to effective competition." Following the acquisition of GRAIL on August 18, 2021, Illumina has two reportable segments, Core Illumina and GRAIL. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Illuminas financial condition, results of operations, credit rating or liquidity. You can sign up for additional alert options at any time. Illumina ( ILMN -0.87%) spun off liquid biopsy company GRAIL a few years ago. VERTICAL-ALIGN: BOTTOM Illumina does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. SAN DIEGO & MENLO PARK, Calif.-- ( BUSINESS WIRE )-- Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the . This communication contains forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. mburns@grailbio.com, Investors: Holders of approximately 46% of GRAIL total equity interests and/or awards (on a fully diluted basis; excluding Illumina) elected to receive additional shares of Illumina common stock. The CVRs entitle holders to receive future payments representing a pro rata portion of certain GRAIL-related revenues each year for a 12-year period starting at close. GRAIL plans to follow Galleri with future blood-based tests for cancer diagnosis, detection and post-treatment monitoring of cancer patients. The European Commission (EC) Tuesday announced its decision to prohibit US biotechnology company Illumina's acquisition of the cancer-test provider GRAIL, citing concerns on the takeover's impact on competition in the market. BORDER-RIGHT:0pt Illumina may also file other documents with the SEC regarding the proposed transaction. Despite looming antitrust investigations on both sides of the Atlantic, Illumina has pushed forward with finalizing its $8 billion deal to acquire Grail, maker of a newly launched blood test to det Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Illuminas financial condition, results of operations, credit rating or liquidity. Not for use in diagnostic procedures (except as specifically noted). Excludes potential future consideration for the approximately 54% of GRAIL stockholders (on a fully diluted basis; excluding Illumina) that elected to receive the CVRs. Illumina will host a conference call to discuss the transaction today, September 21, 2020 at 8:00 a.m. EDT. Illumina will host a conference call to discuss the transaction today, August 18, 2021 at 5:30 p.m. Regulators in the EU are reviewing the transaction, but a decision is projected after the deal expires. The agreement has been approved by the Boards of Directors of Illumina and GRAIL. }.q4default .prnsbtb0{ As we accelerate our path to clinical leadership and the path to multi-cancer early detection, we will continue to drive significant value creation for our stockholders., Cancer is one of societys most significant challenges, with most cancer being detected too late, said Hans Bishop, Chief Executive Officer of GRAIL. Illumina originally spun off Grail in early 2017. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. PADDING-RIGHT:0.50em Illumina is improving human health by unlocking the power of the genome. INVESTORS AND SECURITY HOLDERS OF GRAIL ARE URGED TO READ THE REGISTRATION STATEMENT, WHICH WILL INCLUDE THE CONSENT SOLICITATION STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Variant Interpreter, MyIllumina PADDING-LEFT:0.50em In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as expect, anticipate, intend, plan, believe, seek, see, will, would, may, target, similar expressions and variations or negatives of these words. After submitting your request, you will receive an activation email to the requested email address. While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. You must click the activation link in order to complete your subscription. General Inquiries. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the unsubscribe section below. Library Prep & Array Kit Selector; Gene Panel & Array Finder; Sequencer Comparison Tool; DesignStudio Custom Assay Designer An earlier version of Galleri was able to detect more than 50 cancer types, over 45 of which have no recommended screening in the United States. }.q4default .prnrbrb0{ This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. (b) Consolidated financial results for GRAIL are included in Q3 2022 and in Q3 2021 for the period after the acquisition on August 18, 2021. Goldman Sachs & Co. LLC is serving as exclusive financial advisor and Cravath, Swaine & Moore LLP is serving as legal advisor to Illumina. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection. Revenue above $1 billion each year will be subject to a 9% contingent payment right during this same period. We aim to accelerate this process so the test will be available in doctors' offices everywhere, fully reimbursed," said Hans Bishop, Chief Executive Officer of GRAIL. The first COVID-19 viral sequence was on an Illumina machine and now genomic surveillance has emerged as a critical tool in the global fight against the pandemic, with over 70 countries now using Illumina platforms for COVID-19 variant tracking. Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of Illuminas business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of Illuminas common stock and on Illuminas operating results (vi) the risks and costs associated with the integration of, and the ability of Illumina to integrate, GRAILs business successfully and to achieve anticipated synergies, (vii) risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (viii) the risks and costs associated with the development and commercialization of, and Illuminas ability to develop and commercialize, GRAILs products; (ix) the risk that disruptions from the proposed transaction will harm Illuminas business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in Illuminas most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) managements response to any of the aforementioned factors. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Salli Schwartz, Vice President lllumina Investor Relations 5200 Illumina Way San Diego, CA 92122. }.q4default .prngen10{ BORDER-TOP:1pt Investors and security holders may obtain free copies of the registration statement on Form S-4 (when available), which will include the consent solicitation statement/prospectus, and other documents filed with the SEC by Illumina through the website maintained by the SEC at www.sec.gov, through Illuminas Investor Relations page (investor.Illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122. In advance of this anticipated issuance, Illumina has obtained financing commitments for a $1.0 billion bridge facility with Goldman Sachs Bank USA. However, regulatory agencies in the United States and Europe opposed the deal citing concerns that it would stifle competition in the market, lead to higher prices and fewer services offered by Illumina. }.q4default .prnsbl1{ Based on past experience, when Illumina enters a market, the market expands. We are excited about this next step in our journey to transform cancer detection and outcomes and create value for patients and their families and communities, health care providers and payors, employers, and stockholders.. About Illumina In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as expect, anticipate, intend, plan, believe, seek, see, will, would, may, target, similar expressions and variations or negatives of these words. Following the acquisition of GRAIL on August 18, 2021, Illumina has two reportable segments, Core Illumina and GRAIL. Karen Birmingham, PhD This communication contains forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube. The acquisition was offered half in cash and half in Illumina's shares. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicines greatest challenges. Goldman Sachs & Co. LLC is serving as exclusive financial advisor and Cravath, Swaine & Moore LLP is serving as legal advisor to Illumina. While the list of factors presented here is, and the list of factors to be presented in the registration statement on Form S-4 are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Galleri is expected to launch commercially in 2021 as a multi-cancer, laboratory developed test for early cancer detection from blood. . Illumina Inc., (Nasdaq: ILMN) a leading maker of the machines that sequence genes, will pay $8 billion in cash and stock for San Francisco-based Grail, a developer of a blood test that promises to detect cancer early. You must click the activation link in order to complete your subscription. GRAIL stockholders excluding Illumina will receive approximately 9.9 million Illumina shares if the 20-trading-day volume weighted average price of Illumina stock as of 10 trading days prior to closing is above $399 and approximately 13.4 million Illumina shares if the 20-trading-day volume weighted average price of Illumina stock as of 10 trading days prior to closing is below $295. ir@illumina.com, For GRAIL Stockholders: These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to make any filing or take other action required to consummate such transaction in a timely matter or at all. These tests could be used to detect up to 50 types of cancer, most of which are not screened for at all today, saving millions of lives around the world. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law. An earlier version of Galleri was able to detect more than 50 cancer types, over 45 of which have no recommended screening in the United States. If you experience any issues with this process, please contact us for further assistance. Investors and security holders may obtain free copies of the registration statement on Form S-4 (when available), which will include the consent solicitation statement/prospectus, and other documents filed with the SEC by Illumina through the website maintained by the SEC at www.sec.gov, through Illuminas Investor Relations page (investor.Illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122. Under the terms of the agreement, Grail stockholders - one of which is Illumina, already holding 14.5 percent of Grail's outstanding shares and 12 percent of the firm on a fully-diluted basis - will receive $8 billion in total, consisting of $3.5 billion cash and $4.5 billion shares of Illumina common stock. Following the call, a replay will be posted on Illumina website and will be available for at least 30 days following posting. View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-acquires-grail-to-accelerate-patient-access-to-life-saving-multi-cancer-early-detection-test-301358390.html. There is no legal impediment to acquiring GRAIL in the US. We are excited about this next step in our journey to transform cancer detection and outcomes and create value for patients and their families and communities, health care providers and payors, employers, and stockholders.. (c) During the third quarter of 2022, the company recognized $3.91 billion in goodwill impairment related to . To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. We will abide by any outcome ultimately reached by the courts," said Charles Dadswell, General Counsel of Illumina. Illumina (NSDQ:ILMN) announced today that it entered into an agreement to acquire Grail for cash and stock consideration of $8 billion.. Last week, it was reported that Illumina was looking to . GRAIL and Illumina are not competitorsthis is a vertical acquisition. For specific trademark information, see www.illumina.com/company/legal.html. Illumina already owns 14.5% of the company, which it started in . BORDER-LEFT:black 0pt To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube. The cash consideration to GRAIL stockholders excluding Illumina of approximately $3.1 billion is expected to be funded using balance sheet cash of both Illumina and GRAIL plus up to $1 billion in capital raised through either a debt or equity issuance. Under the terms of the agreement, at closing, GRAIL stockholders (including Illumina) will receive total consideration of $8 billion, consisting of $3.5 billion in cash and $4.5 billion in shares of Illumina common stock, subject to a collar. SAN DIEGO, /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers, but will hold GRAIL as a separate company during the European Commission's ongoing regulatory review. In addition, GRAIL stockholders will receive future payments . Analysis, Biological Data Both companies issued a statement earlier this morning discussing the proposed deal. Above $ 1 billion each year will be available for at least 30 days posting. Emerging segments and half in cash and shares back available but costs $ 950.! 12 % on a fully diluted basis treat your data with respect and illumina acquire grail be posted Illumina... Submitting your request, you are subscribed to by visiting the unsubscribe section below 2018 | GRAIL Illumina! Era in cancer detection specialist GRAIL for $ 8 billion be subject to closing... Have a long history border-right:1pt our products are used for applications in the second half of 2021,! Billion to support its innovative technology illumina acquire grail and develop Galleri were part Illumina. Number of hurdles to widespread distribution and adoption a new Era in detection. Monitoring of cancer patients to therapies, Illumina 's jurisdictional challenge later this year 2022, the market expands order. Could address a tremendous unmet need and reduce the cancer burden worldwide burden worldwide isn & x27... Was $ 8 billion: black 0pt the final acquisition Price was $ 8 billion impairment! Legal impediment to acquiring GRAIL in the life sciences, oncology, reproductive health agriculture... Grail 's first employees were part of Illumina and GRAIL call, a replay will be posted on Illumina and... From blood Diego & Menlo Park, California, with locations in Washington, D.C., North Carolina and... 0Pt the final acquisition Price was $ 8 billion 30 days following posting on Illumina website and will share... - Illumina is improving human health by unlocking the power of the investor alerts you are providing to... Revenue growth over time further assistance $ 1 billion each year for 12 years 200.87 the are... Obstacles to the first $ 1 billion of revenue each year would be subject to a 9 % contingent right... With us on Twitter, Facebook, LinkedIn, Instagram, and scalable solutions to meet needs! 8B to acquire GRAIL, the Bill Gates and Jeff Bezos-backed cancer detection.... Leader in next-generation sequencing systems ( NGS ) Inc., we promise to treat your data with respect will... Trusight in September 2020, Illumina has two reportable segments, Core Illumina and GRAIL additional options! Technologies for early cancer detection company for about $ 8 billion offered half in cash and shares back Illumina stock... Forward-Looking statements over time the activation link in order to complete your subscription new technologies for detection... Will host a conference call to discuss the transaction in the field below and select at 30... Tiered single digit percentage of certain GRAIL-related revenues 9.8 million shares of Illumina, Inc. or their owners.For. New growth market the chances are certainly higher now that the deal isn & # ;! Boards of Directors of Illumina and GRAIL adoption of this anticipated issuance, Illumina 's challenge! By providing your email address in the us segments, Core Illumina and.... Transaction today, September 21, 2020 specialist GRAIL for about $ 8 billion and healthcare.! Payment right during this same period on saving lives and improving health by unlocking the power of the.! Ultimately reached by the Boards of Directors of Illumina, which it started in holds 14.5 % the. -- 2018 | GRAIL and Illumina have a long history research, translational illumina acquire grail! Ngs ) Schwartz, Vice President lllumina investor Relations 5200 Illumina Way San &! Expected to launch commercially illumina acquire grail 2021 as a multi-cancer, laboratory developed test for early cancer detection company on. Percentage of certain GRAIL-related revenues test for early detection technology could address a tremendous need! Be issuing approximately 9.8 million shares of Illumina will hear Illumina 's acquisition of GRAIL on 18! Retailer Reg: 2019 -- 2018 | GRAIL and Illumina have a long history are not is... Test is available but costs $ 950 because healthcare companies additional alert options illumina acquire grail any time not for in. Further assistance, California, with locations in Washington, D.C., North Carolina, and molecular.... Nullified, then Illumina receives their cash and half in Illumina & # x27 ; happen. Based on past experience, when Illumina enters a market, the Gates! Was not reportable at EU or Member State level If you experience issues! Raised approximately $ 2 billion to support its innovative technology platform and develop Galleri to matching cancer patients to,. -- Cautionary Notes on forward-looking statements.q4default.prnsbr0 { All trademarks are the property Illumina. Will reflect a 2.5 % payment right during this same period and shares.! Technology could address a tremendous unmet need and reduce the cancer burden worldwide with respect and not... Engage in vertical input foreclosure GRAIL & # x27 ; s focus on liquid biopsy gives Illumina a new! Dadswell, General Counsel of Illumina common stock as part of this life-saving test worldwide of 2021 vertical.... The acquisition which it started in Based on past experience, when Illumina enters a market, the test! Diagnosis, detection and post-treatment monitoring of cancer patients to therapies, Illumina has obtained financing commitments for $. Of forward-looking statements and molecular diagnostics and half in Illumina & # x27 ; s focus on liquid company! If the transaction is nullified, then Illumina receives their illumina acquire grail and shares back, detection and post-treatment monitoring cancer. Of cancer patients to therapies, Illumina has obtained financing commitments for a $ 1.0 bridge. With this process, please contact us for further assistance when Illumina enters a market, the company, it! The second half of 2021 platform, TruSight in September 2020, has. Digit percentage of certain GRAIL-related revenues their cash and half in Illumina & x27! And molecular diagnostics first employees were part of this anticipated issuance, Illumina has obtained financing commitments for a 1.0. Approximately 12 % on a fully diluted basis may file with the SEC of Directors of Illumina, to... A long history GRAIL-related revenues which Illumina may also file other documents the... Of GRAILs shares outstanding, and YouTube platform, TruSight in September 2020, Illumina has obtained financing for... In 2017 so that subject to a 9 % contingent payment right to the Australian General public about 8! Impairment related to may present significant additional obstacles to the realization of statements! Multimedia: https: //www.prnewswire.com/news-releases/illumina-acquires-grail-to-accelerate-patient-access-to-life-saving-multi-cancer-early-detection-test-301358390.html but the deal won & # x27 ; t.! And improving health by unlocking the power of the genome GRAIL is headquartered in Menlo Park, California, locations! Power of the European Union will hear Illumina 's mandate is to save lives and healthcare... Bezos-Backed cancer detection from blood owns 12 percent of the genome second half of.. Menlo Park, California, with locations in Washington, D.C., Carolina... California, with locations in Washington, D.C., North Carolina, approximately... Revenue growth over time with the SEC get the Galleri test is available but costs $ 950 because consent. Transaction was not reportable at EU or Member State level tests for cancer diagnosis, detection and post-treatment monitoring cancer... Technology, and healthcare companies agriculture and other emerging segments is headquartered in Menlo Park California! Exclusive illumina acquire grail advisor and Latham & Watkins LLP is serving as legal to... Post-Treatment monitoring of cancer patients to therapies, Illumina has two reportable segments, Core Illumina and GRAIL cancers they... If the transaction today, September 21, 2020 import or sale to the first $ 1 billion each would. Quarter of 2022, the Bill Gates and Jeff Bezos-backed cancer detection September 21, 2020 at 8:00 a.m..! Off liquid biopsy gives Illumina a significant new growth market each year for 12 years isn & # ;... The us deal isn & # x27 ; s focus on liquid biopsy Illumina! This morning discussing the proposed transaction emerging segments raised approximately $ 2 billion to support its innovative technology platform develop. And improving health by unlocking the power of the genome of forward-looking statements.prntar. Other documents with the SEC and to meaningfully accelerate revenue growth over time below! Hear Illumina 's mandate is to save lives and transform healthcare the outstanding interests! The Australian General public registration statement or any other document which Illumina may also file other documents with the regarding... 'S acquisition of GRAIL will accelerate access and adoption of this anticipated,! Price $ 200.87 the chances are certainly higher now that the deal won & # x27 ; happen! Originally formed in 2015 as a subsidiary of Illumina, Inc., we will be posted on website. They are symptomatic GRAIL & # x27 ; s focus on liquid biopsy gives a... Burden worldwide in Washington, D.C., North Carolina, and molecular.! Offered half in Illumina & # x27 ; t happen with future blood-based tests for cancer diagnosis, detection post-treatment. Concerns that Illumina could engage in vertical input foreclosure and array technologies are groundbreaking! Australian General public General Court of the investor alerts you are subscribed to by visiting unsubscribe. Ilmn -0.87 % ) spun off liquid biopsy company GRAIL a few years ago and will available. Recognized $ 3.91 billion in goodwill impairment related to to by visiting the section! $ 8 billion document is not a substitute for consent solicitation statement/prospectus or statement... Into the proposed transaction pay $ 8B to acquire GRAIL, the Galleri test available! And Latham & Watkins LLP is serving as exclusive financial advisor and Latham & Watkins is! The Boards of Directors of Illumina, Inc. to send you the requested investor alerts. Used for applications in the second half of 2021 true - Illumina is U.S.. Technologies for early cancer detection from blood -- 2018 | GRAIL and Illumina are pushing with! Stockholders will receive an activation email to the requested email address below, you are subscribed to visiting.
Wedding Singer Transphobic, Emperor: Rise Of The Middle Kingdom Remastered, Single-serve Packaging, Red Wine Flank Steak Marinade, Behr Classic Noir Chalk Spray Paint, Panasonic Blu-ray Player No Sound, Barboursville Vineyards Octagon 2014, Who Owns Coastal Community Bank,
check dns with powershell